Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

This article discusses various aspects of hair loss but reports no new research findings.

This study reported that topical drugs regrew hair in mice.

An arthritis drug helped a person with severe hair loss regrow their hair.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This review highlights that in children, hair loss can be attributed to diverse conditions like alopecia areata and tinea capitis, and stresses the importance of a holistic approach to diagnosis and management, including psychosocial support due to limited effective treatments.

This study found that untargeted hair metabolomics analysis detected significantly altered endogenous biomolecules, potentially serving as biomarkers for identifying oxidative cosmetic hair treatments like bleaching.

This case study reports that a 9-year-old Nepalese boy with tinea capitis successfully recovered with systemic antifungal therapy, though experienced focal alopecia without recurrence at a two-year follow-up.

Alopecia areata treatments should be personalized, using options like steroids, JAK inhibitors, and other therapies based on individual needs.

This systematic review identified that surgical treatments show a positive response for eyebrow and eyelash leukotrichia, while topical tofacitinib appears promising but requires further research to confirm its efficacy.

This study found that FZD2 is crucial for hair follicle formation and postnatal growth in mice and has a novel role in regulating early epidermal development, including stratification and cornification.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.

This case study reports a rare co-occurrence of alopecia areata and vitiligo in a 13-year-old female, suggesting a potential pathogenic link between the two autoimmune skin diseases.

This study elucidated the multi-component and multi-target mechanisms by which TR and Am may provide therapeutic benefits for treating androgenetic alopecia.

This study developed a method using ultra-performance liquid chromatography and mass spectrometry to detect illegal substances in hair loss prevention cosmetics, revealing that some products contained high levels of minoxidil and finasteride, posing safety risks.

This study reported that MALDI-TOF Mass Spectrometry profiling demonstrated nearly 100% sensitivity and specificity in detecting adenomyosis and leiomyoma, revealing potential peptide markers for these conditions.

In this study, tofacitinib was found to be a promising treatment for adolescents with alopecia areata, showing significant hair regrowth in most patients with mild adverse effects, despite limitations like small sample size and lack of control group.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This case report describes a rare instance of sarcoidal granulomatous alopecia areata in a 42-year-old man, with histopathological findings suggesting inflammation but ruling out causes like tuberculosis and syphilis, resulting in treatment with tofacitinib.

This study found that in alopecia areata, epidermal γδ T cells and macrophages contribute to the disease alongside CD8 T cells, with the expression of BST2 marking interferon-driven immune activation in both mouse and human skin, which decreases following treatment with the JAK inhibitor tofacitinib.

In this follow-up study, participants with severe androgenic/estrogenic alopecia showed increased hair growth 10 months after ending vacuum therapy and cosmetic emulsion treatment, highlighting the therapies' potential effectiveness.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

In an animal study, this research explored the use of a self-therapeutic nanoparticle for treating psoriasis in mice, finding that it could prevent and treat psoriatic symptoms as effectively as standard therapies without causing side effects like hair loss and skin wrinkling.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

A new method can almost perfectly distinguish adenomyosis from similar conditions using blood tests.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.